Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.
Howard S
HS
Hochster
Axel
A
Grothey
Barrett H
BH
Childs
D002118:Calcium / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage*; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000517:prevention & control*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D012107:Research Design; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008274:Magnesium; D002118:Calcium